The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP‐9
Open accessAbstract
Aim: To investigate the status of Phosphatidylinositol 3‐kinase (PI3K)/PTEN/AKT/mammalian target of rapamycin (mTOR) pathway and its correlation with clinicopathological features and matrix metalloproteinase‐2, ‐9 (MMP‐2, 9) in human hepatocellular carcinoma (HCC). Methods: PTEN, Phosphorylated AKT (p‐AKT), Phosphorylated mTOR (p‐mTOR), MMP‐2, MMP‐9 and Ki‐67 expression levels were evaluated by immunohistochemistry on tissue microarrays containing 200 HCCs with paired adjacent non‐cancerous liver tissues. PTEN, MMP‐2 and MMP‐9 mRNA levels were determined by real‐time RT‐PCR in 36 HCCs. The relationships between PI3K/PTEN/AKT/mTOR pathway and clinicopathological factors and MMP‐2, 9 were analyzed in HCC. Results: In HCC, PTEN loss and overexpression of p‐AKT and p‐mTOR were associated with tumor grade, intrahepatic metastasis, vascular invasion, TNM stage and high Ki‐67 labeling index (P < 0.05). PTEN loss was correlated with p‐AKT, p‐mTOR and MMP‐9 overexpression. Furthermore, PTEN and MMP‐2, 9 mRNA levels were down‐regulated and up‐regulated in HCC compared with paired non‐cancerous liver tissues, respectively (P < 0.01). PTEN, MMP‐2 and MMP‐9 mRNA levels were correlated with tumor stage and metastasis. There was an inverse correlation between PTEN and MMP‐9 mRNA expression. However, PI3K/PTEN/AKT/mTOR pathway was not correlated with MMP‐2. Conclusions: PI3K/PTEN/AKT/mTOR pathway, which is activated in HCC, is involved in invasion and metastasis through up‐regulating MMP‐9 in HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Llovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Overall, C. M., & Kleifeld, O. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1821 · Cited by 1,214
Tenets of PTEN Tumor Suppression
Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,034
Hepatocellular carcinoma: Recent trends in the United States
El-Serag, H. B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.013 · Cited by 972
The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W., & Leal, J. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908784293659 · Cited by 887
Sun, H., Lesche, R., Li, D.-M., Liliental, J., Zhang, H., Gao, J., Gavrilova, N., Mueller, B., Liu, X., & Wu, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6199 · Cited by 796
Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production
DOHOON, K., SUNHONG, K., HYONGJONG, K., SANG‐OH, Y., AN‐SIK, C., KYOUNG SANG, C., & JONGKYEONG, C. (2001) · The FASEB Journal · doi:10.1096/fj.01-0198com · Cited by 489
Chung, T., Moon, S., Chang, Y., Ko, J., Lee, Y., Cho, G., Kim, S., Kim, J., & Kim, C. (2004) · The FASEB Journal · doi:10.1096/fj.04-2126com · Cited by 456
Schafer, D. F., & Sorrell, M. F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09148-x · Cited by 453
Matrix metalloproteinases in tumor invasion: Role for cell migration
Nabeshima, K., Inoue, T., Shimao, Y., & Sameshima, T. (2002) · Pathology International · doi:10.1046/j.1440-1827.2002.01343.x · Cited by 446
Targeting the mTOR signaling network in cancer
Chiang, G. G., & Abraham, R. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.001 · Cited by 327
Activation of PI3K‐Akt signaling pathway promotes prostate cancer cell invasion
Shukla, S., MacLennan, G. T., Hartman, D. J., Fu, P., Resnick, M. I., & Gupta, S. (2007) · International Journal of Cancer · doi:10.1002/ijc.22862 · Cited by 316
Cheng, J. C.-H., Chou, C. H., Kuo, M. L., & Hsieh, C.-Y. (2006) · Oncogene · doi:10.1038/sj.onc.1209706 · Cited by 298
Chung, T., Lee, Y., & Kim, C. (2004) · The FASEB Journal · doi:10.1096/fj.03-1429fje · Cited by 288
Fransvea, E., Angelotti, U., Antonaci, S., & Giannelli, G. (2008) · Hepatology · doi:10.1002/hep.22201 · Cited by 253
Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
Jiang, B.-H., & Liu, L.-Z. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.03.001 · Cited by 243
Clinical role of MMP‐2/TIMP‐2 imbalance in hepatocellular carcinoma
Giannelli, G., Bergamini, C., Marinosci, F., Fransvea, E., Quaranta, M., Lupo, L., Schiraldi, O., & Antonaci, S. (2002) · International Journal of Cancer · doi:10.1002/ijc.1635 · Cited by 187
Sieghart, W., Fuereder, T., Schmid, K., Cejka, D., Werzowa, J. M., Wrba, F., Wang, X., Gruber, D., Rasoul‐Rockenschaub, S., Peck‐Radosavljevic, M., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000252780.42104.95 · Cited by 163
Januś, A., Robak, T., & Smolewski, P. (2005) · PubMed · Cited by 115
Martelli, A. M., Tazzari, P. L., Evangelisti, C., Chiarini, F., Blalock, W. L., Billi, A. M., Manzoli, L., McCubrey, J. A., & Cocco, L. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707781368423 · Cited by 114
Davies, M. A., Kim, S. J., Parikh, N. U., Dong, Z., Bucana, C. D., & Gallick, G. E. (2002) · PubMed · Cited by 110
Giannelli, G., Fransvea, E., Bergamini, C., Marinosci, F., & Antonaci, S. (2003) · PubMed · Cited by 97
Stewart, A. L., Mhashilkar, A. M., Yang, X. H., Ekmekçioglu, S., Saito, Y., Sieger, K., Schrock, R. D., Onishi, E., Swanson, X., Mumm, J. B., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402025 · Cited by 84
Potential role of leptin expression in hepatocellular carcinoma
Wang, S.-N., Yeh, Y.-T., Yang, S., Chai, C.-Y., & Lee, K.-T. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.035477 · Cited by 59
Cited by
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Zou, Z., Tao, T., Li, H., & Zhu, X. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00396-1 · Cited by 927
Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer
Koundouros, N., & Poulogiannis, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00160 · Cited by 415
The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets
Yang, J. D., Nakamura, I., & Roberts, L. R. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.007 · Cited by 390
Wu, Q., Zhou, L., Lv, D., Zhu, X., & Tang, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0739-0 · Cited by 281
Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Huang, S., & Zhou, H. (2011) · Current Protein & Peptide Science · doi:10.2174/138920311795659407 · Cited by 270
Metadata
- Authors
- Chen, J., Wang, Q., Fu, X., Huang, X., Chen, X., Cao, L., Chen, L., Tan, H., Li, W., Bi, J., & Zhang, L.
- Venue
- Hepatology Research
- Publisher
- Wiley
- Published
- 2009-01-21
- Volume
- 39
- Issue
- 2
- Pages
- 177-186
- ISSN
- 1386-6346 (ISSN-L)
- 1872-034X
- OpenAlex
- W1981406217
- Cited by
- 342
- References
- 29
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.